C4 Therapeutics, Inc. (CCCC) income statement
CCCCNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 9/304% below fair value
$2.48−0.05 (-2.17%)
Close on Nov 18, 2026Market cap $304.49MP/E –Yield –
C4 Therapeutics, Inc. financial ratios
See a number that looks wrong?